一品红最新一期业绩显示，截至2025一季报，公司营业总收入3.77亿元、同比减少39.48%，归属净利润 5658.85万元，同比减少43.70%，扣非净利润1518.94万元，同比减少84.50%，流动比率1.127、速动比率 0.981、资产负债率62.08%。 金融界消息 截至2025年8月1日收盘，一品红（300723）报收于75.72元，下跌2.37%，换手率2.67%，成 交量11.14万手，成交金额8.68亿元。 资金流向方面，今日主力资金净流入3192.02万元，占比成交额3.68%。其中，超大单净流出268.89万 元、占成交额0.31%，大单净流入3460.91万元、占成交额3.99%，中单净流出流入271.05万元、占成交 额0.31%，小单净流出3463.07万元、占成交额3.99%。 通过天眼查大数据分析，一品红药业集团股份有限公司共对外投资了12家企业，参与招投标项目2次， 知识产权方面有商标信息308条，专利信息16条，此外企业还拥有行政许可9个。 来源：金融界 天眼查商业履历信息显示，一品红药业集团股份有限公司，成立于2002年，位于广州市，是一家以从事 医药制造业为主的企业。 ...

（文章来源：每日经济新闻） 每经AI快讯，一品红涨4.98%，报81.42元/股，股价再创新高，总市值突破367.76亿元，成交额达3.51亿 元。 ...

证券日报网讯 7月31日，一品红发布公告称，公司全资子公司广州市联瑞制药有限公司于近日收到国家 药品监督管理局核准签发的关于西咪替丁注射液的《药品注册证书》。 （文章来源：证券日报） ...

证券日报网讯 7月31日，一品红发布公告称，公司全资子公司广州一品红制药有限公司于近日收到国家 药品监督管理局核准签发的关于复方聚乙二醇电解质散（Ⅲ）的《药品注册证书》。 （文章来源：证券日报） ...

Group 1 - Jiejia Weichuang expects a net profit of 1.7 billion to 1.96 billion yuan for the first half of 2025, representing a year-on-year increase of 38.65% to 59.85% [1] - Micron Biotech's CS231295 clinical trial application has been approved by the FDA for treating advanced solid tumors [1] - Sinopec anticipates a net profit of 20.1 billion to 21.6 billion yuan for the first half of 2025, a decrease of 39.5% to 43.7% year-on-year [2] Group 2 - High Energy Environment has obtained a loan commitment letter from a financial institution for share repurchase [2] - Electric Power Investment Energy received a warning letter from the Inner Mongolia Securities Regulatory Bureau for inadequate disclosure in its semi-annual report [3] - Zhejiang University Net New won a bid for an intelligent engineering project worth 94.2712 million yuan [5] Group 3 - Daodaoquan reported a net profit of 181 million yuan for the first half of 2025, a year-on-year increase of 563.15% [8] - New Light Optoelectronics expects a net loss of 19 million to 23 million yuan for the first half of 2025 [9] - Aihua Pharmaceutical's two probiotic powder registration applications have been accepted [10] Group 4 - Xinhui Electric's subsidiary signed a product sales framework contract for commercial and household robots [11] - Baida Precision Engineering's subsidiary obtained 134,500 square meters of industrial land use rights [12] - Haiyang Technology's chief engineer resigned for personal reasons [13] Group 5 - Tianhe Magnetic Materials received a project filing notice for a 12,000-ton magnetic material deep processing project [22] - Wanlima is the pre-selected unit for a procurement project worth 43.835 million yuan from China Southern Airlines [24] - Yipin Hong's subsidiaries obtained two drug registration certificates [25] Group 6 - Zhejiang Jiaoke's subsidiary signed new construction projects worth 4.783 billion yuan in the second quarter [27] - Shenglan Co. received approval for issuing convertible bonds [29] - Jimi Technology expects a net profit of 88.6622 million yuan for the first half of 2025, a year-on-year increase of 2062.33% [31] Group 7 - Dingtong Technology reported a net profit of 115 million yuan for the first half of 2025, a year-on-year increase of 134.06% [32] - Huaheng Biological is planning to list on the Hong Kong Stock Exchange [34] - Yuntian Lihui submitted an application for H-share issuance and listing on the Hong Kong Stock Exchange [36] Group 8 - Nanchip Technology expects a net profit of 108.8 million to 133.1 million yuan for the first half of 2025, a decrease of 35.09% to 47.03% year-on-year [43] - Anglikang's Mesobam injection has received a drug registration certificate [44] - Jida Zhengyuan's shareholder plans to reduce their stake by up to 0.998% [45]

Group 1 - Shenglan Co., Ltd. has received approval from the China Securities Regulatory Commission for the issuance of convertible bonds to unspecified objects [1] - Yipin Hong's wholly-owned subsidiary, Guangzhou Yipin Pharmaceutical, has obtained the registration certificate for Compound Polyethylene Glycol Electrolyte Powder (III), qualifying it to sell this specification of drug in the domestic market [1] - Zhejiang Jiaokao disclosed its second-quarter construction industry operating situation, reporting that its subsidiary, Zhejiang Jiaogong, won and signed 207 new projects in the second quarter, amounting to 4.783 billion yuan; for the first half of the year, a total of 539 new projects were won and signed, totaling 21.355 billion yuan [1] Group 2 - Weilon Co., Ltd. is approaching the final half trading day before the "Weilon Convertible Bonds" stop conversion and redemption; after the market closes on July 31, unconverted "Weilon Convertible Bonds" will cease conversion, and the remaining convertible bonds will be forcibly redeemed at a price of 100.485 yuan per bond, which may result in losses for investors [1]

此次公司获得复方聚乙二醇电解质散(Ⅲ)注册证书，标志着公司具备了在国内市场销售该规格药品的资 格，将进一步丰富公司产品管线和产品品类，增强了公司的核心竞争力。 一品红（300723）(300723.SZ)发布公告，公司全资子公司广州一品红制药有限公司于近日收到国家药 品监督管理局核准签发的关于复方聚乙二醇电解质散(Ⅲ)的《药品注册证书》，复方聚乙二醇电解质散 (Ⅲ)适应症为：用于以下情况之前的患者结肠清洁准备：--内窥镜或放射检查--结肠手术，本品适用于成 人。 ...

Core Viewpoint - The company Yipinhong (300723.SZ) has received the drug registration certificate for Compound Polyethylene Glycol Electrolyte Powder (III) from the National Medical Products Administration, allowing it to sell this product in the domestic market, which enhances its product pipeline and core competitiveness [1] Group 1 - The registration certificate is specifically for the use of the product in bowel cleansing preparation for patients prior to procedures such as endoscopy, radiological examinations, and colorectal surgery, applicable to adults [1] - This approval signifies the company's capability to market this specific drug formulation in China, thereby expanding its product offerings [1] - The introduction of this product is expected to strengthen the company's competitive edge in the pharmaceutical industry [1]

Core Viewpoint - The company has received the drug registration certificate for Cimetidine Injection from the National Medical Products Administration, allowing it to sell this product in the domestic market, which enhances its competitiveness in the chronic disease medication sector [1] Group 1 - The company's wholly-owned subsidiary, Guangzhou Lianrui Pharmaceutical Co., Ltd., has obtained the registration certificate for Cimetidine Injection, indicating its eligibility to market this drug in China [1] - Cimetidine Injection is indicated for the treatment of gastrointestinal ulcers, expanding the company's product pipeline and categories [1] - This approval is expected to strengthen the company's position in the chronic disease medication market [1]

Core Viewpoint - The company Yipinhong (300723.SZ) has received the drug registration certificate for Cimetidine Injection from the National Medical Products Administration, allowing it to sell this product in the domestic market, which enhances its competitiveness in the chronic disease medication sector [1]. Group 1 - The company's wholly-owned subsidiary, Guangzhou Lianrui Pharmaceutical Co., Ltd., has obtained the registration certificate for Cimetidine Injection, indicating its eligibility to market this drug in China [1]. - The indication for Cimetidine Injection is for the treatment of gastrointestinal ulcers, which expands the company's product offerings [1]. - This approval will further enrich the company's product pipeline and categories, strengthening its position in the chronic disease medication field [1].